Pediatric Liver Center, Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ther Clin Risk Manag. 2009 Jun;5(3):651-60. doi: 10.2147/tcrm.s5078. Epub 2009 Aug 20.
Since 1992, the maternal-fetal route of transmission has become the dominant route for acquisition of hepatitis C (HCV) infection by children. With increasing knowledge of antiviral treatment for HCV infection, the main goal of therapy is to achieve a sustained virological response (SVR) as defined by undetectable serum HCV RNA by polymerase chain reaction assay six months after cessation of therapy. In young children, interferon therapy is more effective than in adults with chronic HCV infection (CHC). Although children clearly have a milder degree of liver pathology, data have indicated that hepatic inflammation from HCV infection can progress to fibrosis or cirrhosis in children. Hepatocellular carcinoma has been reported in adolescents with CHC. In this article, recent improvements in therapy of children with CHC and in the clinical development of new emerging drugs with potential use in children will be reviewed.
自 1992 年以来，母婴传播途径已成为儿童感染丙型肝炎（HCV）的主要途径。随着对 HCV 感染抗病毒治疗认识的不断提高，治疗的主要目标是通过聚合酶链反应检测到治疗停止后六个月血清 HCV RNA 不可检测来实现持续病毒学应答（SVR）。在幼儿中，干扰素治疗比慢性丙型肝炎感染（CHC）的成人更有效。尽管儿童的肝病理程度明显较轻，但数据表明，HCV 感染引起的肝炎症可在儿童中进展为纤维化或肝硬化。已报道青少年 CHC 患者发生肝细胞癌。本文将综述儿童 CHC 治疗的最新进展以及具有儿童应用潜力的新型新兴药物的临床开发。
